Navigation Links
Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new six month safety and efficacy results from its fourth Phase II clinical trial using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. Consistent with previously reported six month (Petal Study) and three month (Lilac Petal Study) results, a favorable safety profile and clinically meaningful efficacy have again been confirmed through month six of the Lilac Petal Study. This newly available data also provides clinical confirmation of Neurocrine's extensive pharmacologic modeling related to the elagolix dose-response continuum. The outcome of primary interest at month six was the impact of the elagolix 250 mg dose on bone mineral density (BMD) as measured by dual energy X-ray absorptiometry (DXA) scanning.

Over the six month treatment period, elagolix 150 mg once daily had minimal impact on BMD (-0.80% mean change from baseline, femur; -0.66% mean change from baseline, spine). The 250 mg once daily dose, as expected, had slightly greater percentage change from baseline at month six (-1.0% femur, -1.6% spine). The 150 mg once daily BMD profile in this Lilac Petal Study is consistent with that previously demonstrated in the six-month Petal Study.

"We selected the 150 mg and 250 mg once daily doses for this study based upon predictions generated from extensive modeling of dose, estradiol and bone mineral density relationships. Prior to this study we anticipated that the 250 mg dose would provide exposure such that we would start to see an increased impact on bone mineral density in a small portion of study subjects. The Lilac Petal data confirm that our modeling of the dose-response curve was accurate," said C
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
2. Blue Marble Energy Corp. Announces Successful Close of Series A Financing
3. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
4. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
5. Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UKs Veterinary Laboratories Agency
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
8. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
9. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
10. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Fla. , Sept. 11, 2014 /PRNewswire/ ... anti-infective pharmaceuticals, announced today that the United ... a ,Notice of Allowance, for patent application ... Uses,.  The ,486 patent application relates to ... through gene-silencing and can be designed to ...
(Date:9/11/2014)... Entries are now being accepted for the annual ... colleagues within the healthcare industry select who wins. Now in ... best in healthcare creative campaigns. The awards are unique in ... and wellness industry. All entries are placed online, and healthcare ... each category. , “No one knows what it takes ...
(Date:9/11/2014)... September 11, 2014 Genera Energy ... innovation and supply chain advancements, recently introduced its newest ... BIN-SPEC delivers a consistent biomass product to a customer’s ... a lower cost. , “After producing and harvesting ... place to convert a field crop into a uniform ...
(Date:9/11/2014)... 11, 2014 Central Florida board-certified veterinary ... partnerships with several Brevard County animal hospitals to bring ... been working in the area since January 2006, credentialed ... 2008, and is happy to now offer his expertise ... Christiansen has used stem cell therapy with Vet-Stem, Inc. ...
Breaking Biology Technology:Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 2Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 3PM360 Now Accepting Entries for 2014 Pharma Choice Awards 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 3Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3
... Without effective and proper networking techniques, you may not be ... to other professionals. While people have their own networking style ... , ,You need to do what works best for you ... to learn new ideas about networking from other professionals who ...
... Neurognostics , a home-grown Milwaukee medical device company, finished ... first to take advantage of Wisconsin's new tax credits for ... an investment. , ,Neurognostics oversubscribed on its $1 million angel ... af Neurognostics. As a tech-based research and development company, the ...
... project to match genetic information from Alzheimer's patients with ... ,The two-year project is the first to tap the ... for its Personalized Medicine Research Project, one of the ... of electronic medical records, the project aims to develop ...
Cached Biology Technology:Improve your networking skills by learning from other professionals 2Improve your networking skills by learning from other professionals 3Improve your networking skills by learning from other professionals 4Milwaukee firm among first to use Act 255 tax credits in investor pitch 2Milwaukee firm among first to use Act 255 tax credits in investor pitch 3Milwaukee firm among first to use Act 255 tax credits in investor pitch 4Marshfield study mixes DNA into electronic medical record to screen for Alzheimer's 2Marshfield study mixes DNA into electronic medical record to screen for Alzheimer's 3
(Date:9/11/2014)... Rice Research Institute of Iran have discovered that ... Asia, has changed its host preferences in order to adjust ... adaptation for biological control of problematic weeds in rice fields ... have been described in the open access journal ... permixtana have been so far reported to feed ...
(Date:9/11/2014)... , Sept. 11, 2014 NXT-ID, Inc. (Nasdaq: ... the growing mobile commerce market, announced today that its shares ... commenced trading on The Nasdaq Capital Market. The common stock ... "NXTDW," respectively. As of today, the Company,s common stock will ... quoted on the OTCQB will now be traded on Nasdaq. ...
(Date:9/11/2014)... have long been fascinated by animals, ability to ... now, no studies have directly tested whether those ... of fighting than they would using the fighting ... of Montana recently discovered each species, weapons are ... of fighting., The groundbreaking research, conducted over the ...
Breaking Biology News(10 mins):Unusual host preference of a moth species could be useful for biological control 2UM research reveals secrets of animal weapons 2
... cure, is a common expression, but what happens if preventative ... women are going out of their way not to be ... recent paper by Larsson et al. in AIDS ... and cost-effectively prevented using a short course of antiretroviral therapy. ...
... Researchers from Stony Brook University Medical Center in New ... genuine ancient human species and not a descendant of healthy ... remains of a well-preserved female specimen, researchers determined the "hobbit" ... version of modern humans. Details of the study appear ...
... In an advance with overtones of Star Trek phasers and ... of an internal on-off "switch" that paralyzes animals when exposed ... even when the light is turned off. When exposed to ... study appears in the Journal of the American Chemical ...
Cached Biology News:'Hobbits' are a new human species -- according to the statistical analysis of fossils 2
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Whole Genome Amplification Kit utilizes a ... of genomic DNA and conversion of ... library molecules flanked by universal priming ... amplification of the library molecules using ...
... ultra-pure recombinant thermostable DNA polymerase obtained by ... polymerase gene in E. coli, Concentration: 5U/ul, ... Thermo Fisher Scientific, the world leader in ... to make the world healthier, cleaner and ...
... Analysis of large numbers of samples may ... system which requires minimum operator attention. ... PowerStream software and interface CE 4900. The ... operates in Windows XP and Windows 98 and ...
Biology Products: